Business Context and Reporting Period
This Form 8-K filing by Lineage Cell Therapeutics, Inc. (LCTX) covers events occurring on June 9, 2026, and the Annual Meeting of Shareholders held on June 10, 2026. The report details the outcomes of shareholder votes and a strategic decision regarding a grant application.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and operational updates rather than financial performance.
Material Changes and Operational Updates
- Grant Application Withdrawal: On June 9, 2026, the Company withdrew its application for a Clinical Trial (CLIN2) award (the "CIRM Grant") from the California Institute for Regenerative Medicine (CIRM). This grant was intended to support the clinical development of OPC1 for spinal cord injuries (SCI).
- Development Continuity: Management stated that the withdrawal does not impact the ongoing DOSED clinical study, which evaluates a novel spinal cord delivery device for administering OPC1 in subacute and chronic SCI participants.
Shareholder Voting Results
Shareholders voted on three matters at the Annual Meeting:
- Election of Directors: All seven nominees were elected. Votes ranged from approximately 89.9 million to 90.5 million "For" votes, with broker non-votes totaling 73,917,854 for each nominee.
- Ratification of Auditors: Shareholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 163,825,928 "For" versus 659,670 "Against."
- Executive Compensation: Shareholders approved, on an advisory basis, the compensation for named executive officers. The vote was 88,328,168 "For" versus 2,600,932 "Against."
Outlook, Risks, and Contingencies
The withdrawal of the CIRM Grant application represents a contingency in the Company's funding strategy for the OPC1 program. However, management explicitly noted that the clinical development timeline for the DOSED study remains unaffected. No specific financial risks or guidance were disclosed in this filing.
Key Facts for Investor Verification
- Verify the impact of the CIRM Grant withdrawal on the Company's cash runway and future funding plans for the OPC1 program.
- Review the definitive Proxy Statement filed on April 29, 2026, for detailed context on the executive compensation advisory vote.
- Monitor upcoming updates on the DOSED clinical study to confirm that development milestones are proceeding as planned despite the grant withdrawal.